Viva Biotech Holdings
Viva Biotech Holdings, an investment holding company, engages in the provision of structure-based drug discovery services to biotechnology and pharmaceutical customers worldwide. The company provides discovery biology services, including protein expression and purification, structural biology, hit discovery, bioassay, biomolecular interaction, and pharmacology and DMPK; chemistry services, such a… Read more
Market Cap & Net Worth: Viva Biotech Holdings (VBIZF)
Viva Biotech Holdings (PINK:VBIZF) has a market capitalization of $631.42 Million ($631.42 Million) as of March 18, 2026. Listed on the PINK stock exchange, this USA-based company holds position #12759 globally and #5414 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Viva Biotech Holdings's stock price $0.30 by its total outstanding shares 2109650305 (2.11 Billion).
Viva Biotech Holdings Market Cap History: 2019 to 2025
Viva Biotech Holdings's market capitalization history from 2019 to 2025. Data shows change from $1.25 Billion to $631.42 Million (-10.44% CAGR).
Viva Biotech Holdings Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Viva Biotech Holdings's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.12x
Viva Biotech Holdings's market cap is 0.12 times its annual revenue
1728.56x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
1.43x
Viva Biotech Holdings's market cap is 1.43 times its annual earnings
0.11x
Higher than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2019 | $1.25 Billion | $323.06 Million | $265.87 Million | 3.88x | 4.72x |
| 2020 | $2.50 Billion | $696.96 Million | -$386.88 Million | 3.59x | N/A |
| 2021 | $1.27 Billion | $2.10 Billion | $287.55 Million | 0.60x | 4.40x |
| 2022 | $502.94 Million | $2.38 Billion | -$528.48 Million | 0.21x | N/A |
| 2023 | $260.33 Million | $2.16 Billion | -$116.11 Million | 0.12x | N/A |
| 2024 | $239.66 Million | $1.99 Billion | $167.29 Million | 0.12x | 1.43x |
Competitor Companies of VBIZF by Market Capitalization
Companies near Viva Biotech Holdings in the global market cap rankings as of March 18, 2026.
Key companies related to Viva Biotech Holdings by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Viva Biotech Holdings Historical Marketcap From 2019 to 2025
Between 2019 and today, Viva Biotech Holdings's market cap moved from $1.25 Billion to $ 631.42 Million, with a yearly change of -10.44%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $631.42 Million | +163.47% |
| 2024 | $239.66 Million | -7.94% |
| 2023 | $260.33 Million | -48.24% |
| 2022 | $502.94 Million | -60.27% |
| 2021 | $1.27 Billion | -49.40% |
| 2020 | $2.50 Billion | +99.53% |
| 2019 | $1.25 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Viva Biotech Holdings was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $631.42 Million USD |
| MoneyControl | $631.42 Million USD |
| MarketWatch | $631.42 Million USD |
| marketcap.company | $631.42 Million USD |
| Reuters | $631.42 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.